Regeneron Stock Forecast: REGN Jumps 13% as Full Dupixent Profits Kick In, With $930.46 the Next Test

Revenue rose 36% to $5.12 billion, against about $4.58 billion expected, and non-GAAP EPS, which leaves out items such as stock-based pay, jumped 70% to $20.07, against an estimate of about $16.51, according to Trefis. GAAP EPS rose 35% to $18.45. CEO Leonard Schleifer called it "an outstanding quarter," with Dupixent, EYLEA HD and Libtayo each setting sales records.

Collaboration revenue from Sanofi rose 68% to $2.72 billion. Regeneron had been paying back its share of past development costs out of its Dupixent profits, and that balance was fully repaid at the end of Q2. From Q3 onward, the full profit share flows through, which makes this a lasting step-up rather than a one-time gain.

Dupixent, whose sales Sanofi records, grew 35% to $6.5 billion in the quarter, so the profit pool Regeneron shares in is still expanding.

In the US, EYLEA HD sales jumped 62% to $699 million, while the original EYLEA fell 41% to $400 million. Together, the two brought in about $1.1 billion, down only about 1% from a year earlier, with EYLEA HD now nearly two-thirds of the total. The higher-dose version is now offsetting most of the decline. Libtayo, Regeneron's cancer drug, rose 51% to $550 million.

Regeneron also expanded its Sanofi alliance to cover four next-generation, long-acting immunology antibodies. Sanofi will pay $1.0 billion upfront, which Regeneron will book as collaboration revenue in Q4, plus up to $7.0 billion in milestones, and the two companies will share costs and profits equally. That gives Regeneron a path to extend its immunology business beyond Dupixent.

Other news added support, including a $270 million Inmazeb supply deal with BARDA for Ebola preparedness through 2031, and Libtayo data showing a 37% lower risk of death in high-risk skin cancer after nearly four years of follow-up.

TD Cowen raised its target to $980 and Canaccord to $922, while Evercore trimmed its target to $850, according to StocksToTrade. After a 26% October rally, the stock already trades near several targets. The main risks are Regeneron's growing reliance on Dupixent and further declines in the original EYLEA. In my view, the Sanofi step-up looks durable, but much of it is now in the price.

The breakout shows clearly on the daily chart. REGN opened sharply higher on Friday, pushed through $870.49 and closed just below $930.46, the 227.2% Fibonacci extension, a level traders use to project how far a move can run. The uptrend is strong, with price well above the rising 50-day and 100-day EMAs, moving averages that give more weight to recent prices, at $784.71 and $761.50.

RSI, a momentum gauge that runs from 0 to 100, has jumped to about 79, well above 70, the overbought line, and the MACD, a trend-following momentum indicator, is climbing sharply. Momentum is strong, but after a move this large a pause or pullback would be normal.

REGN Price Chart - Source: Tradingview

A daily close above $930.46 could open the way for $961.85, then $996.05. On the downside, $870.49 is now key support, and a close below it could send REGN back toward $813.87.

I'm bullish while REGN holds above $870.49, though overbought conditions could bring a short pause first.

Key Levels

• Last close: $927.89, up 13.33% on Friday, October 30
• Support: $870.49, $813.87, $784.71
• Resistance: $930.46, $961.85, $996.05
• RSI: 79.11, deep in overbought territory
• Bullish trigger: Daily close above $930.46
• Bearish trigger: Daily close below $870.49

Why did Regeneron stock jump after earnings?

Regeneron rose 13.33% on Friday after Q3 revenue of $5.12 billion and non-GAAP EPS of $20.07 beat estimates by a wide margin, helped by its first quarter of full Dupixent profits from Sanofi and a new Sanofi deal worth $1 billion upfront.

What is the Regeneron stock forecast now?

The bias is bullish above $870.49 on the daily chart. A daily close above $930.46 targets $961.85 and $996.05, while a close below $870.49 opens $813.87.

Regeneron's quarter showed a lasting earnings step-up from full Dupixent profits, not just a one-time beat. The level that matters is $930.46. I expect a short pause with RSI this high, but a daily close above it would open $961.85, while a close below $870.49 would weaken the breakout.